Dr. Aksinija A Kogan
Principal Investigator
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland, United States
AML Research
Biography
Dr. Aksinija A Kogan is a researcher at Johns Hopkins Kimmel Cancer Center specializing in acute myeloid leukemia (AML) treatment optimization. Her work focuses on drug combination strategies and optimizing therapeutic approaches for AML patients.
Dr. Kogan's research contributes to identifying effective drug combinations that can improve outcomes for AML patients while managing treatment-related toxicity. Her work involves both laboratory research and clinical application of optimized treatment protocols.
Official Profile
Learn more about Dr. Aksinija A Kogan's clinical practice and research at Johns Hopkins Kimmel Cancer Center:
View official profile at Johns Hopkins Kimmel Cancer CenterResearch Contributions
Research Impact
Dr. Aksinija A Kogan has authored 69+ peer-reviewed publications contributing to advances in leukemia treatment. Their research has been published in leading medical journals and presented at major national and international conferences.
Explore Additional Research
Find additional publications and research by Dr. Aksinija A Kogan:
Search PubMed for publications by Dr. Aksinija A KoganCurrent Research Projects
AML Active
Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia.
Principal Investigator: Dr. Aksinija A Kogan
Institution: Johns Hopkins Kimmel Cancer Center
Location
Baltimore, Maryland
Timeline
Start: January 2021
Completion: December 2024